The right clothing can help you minimize atopic dermatitis flares. Learn about common clothing triggers, plus tips on ...

The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric ...

Patients with moderate-to-severe atopic dermatitis achieve similar improvements in skin severity, itch, and quality of life ...

The nationwide analysis revealed that individuals with AD had more than a sevenfold greater risk of fibromyalgia compared ...

Incyte Biosciences Canada today announced that Health Canada has approved Opzelura® (ruxolitinib (as ruxolitinib phosphate)) ...

The FDA approved Zoryve cream 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis, ...

Evommune, Inc. targets a $100M IPO to fund inflammation therapies. Click for more about EVMN stock, its drug pipeline, market ...

The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...